VivoSeq
Other

Survivorship

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

Survivorship is an early-stage landscape with 0 programs across 1 company. The most active players are Regeneron.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Regeneron logo

Regeneron

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Not yet recruiting1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Survivorship Promotion In Reducing IGF-1 Trial
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02431676·121 enrolled
CemiplimAb Survivorship Epidemiology
Completed·Regeneron logoRegeneron·N/A·NCT03836105·287 enrolled
Bridging the Gap in Psychosocial Care for Cancer Survivors: Integrating Digital Screening With Navigation Call
Not yet recruiting·UUniversity Hospital, Basel, Switzerland·Preclinical·NCT07672314·50 enrolled
Brief Behavioral Activation for the Treatment of Depression in Older Adult Cancer Survivors
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05574127·90 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)